Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference
February 27 2020 - 8:00AM
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s
health innovation, today announced that Sabrina Martucci Johnson,
President and Chief Executive Officer, will present at the Cowen
40th Annual Health Care Conference on Wednesday, March 4, 2020, at
8:40 a.m. Eastern Time. The conference will be held at the Boston
Marriott Copley Place in Boston, Massachusetts.
A live webcast of the presentation will be
available via the Investors section of the Company’s website at
https://ir.darebioscience.com/events-presentations. An
archive of the presentation will be available for replay through
March 18, 2020.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s health. The company’s mission is to
identify, develop and bring to market a diverse portfolio of
differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential
first-in-category candidates in clinical development: Ovaprene®, a
hormone-free, monthly contraceptive intravaginal ring whose U.S.
commercial rights are under a license agreement with Bayer;
Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to
treat female sexual arousal disorder utilizing the active
ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of
clindamycin phosphate 2% to treat bacterial vaginosis via a single
application; and DARE-HRT1, a combination bio-identical estradiol
and progesterone intravaginal ring for hormone replacement therapy
following menopause. To learn more about Daré’s full portfolio of
women’s health product candidates, and mission to deliver
differentiated therapies for women, please visit
www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using its investor relations website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels
to distribute material information about the company, and may also
use social media to communicate important information about the
company, its finances, product candidates, clinical trials and
other matters. The information Daré posts on its investor
relations website or through social media channels may be deemed to
be material information. Daré encourages investors, the media, and
others interested in the company to review the information Daré
posts on its investor relations website
(https://darebioscience.gcs-web.com/) and to follow these Twitter
accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the
list of social media channels the company may use to communicate
information will be posted on the investor relations page of the
company's website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:Lee
Roth Burns McClellan lroth@burnsmc.com 212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:Jake
Robison Canale Communications jake@canalecomm.com
619.849.5383
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2023 to Apr 2024